QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: dmd.108.023184v1 36/12/2419    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jordheim, L. P. Articles by Tavtigian, S. V. Search for Related Content PubMed PubMed Citation Articles by Jordheim, L. P. Articles by Tavtigian, S. V.

SHORT COMMUNICATION

Differential Allelic Expression in Leukoblast from Patients with Acute Myeloid Leukemia Suggests Genetic Regulation of CDA, DCK, NT5C2, NT5C3, and TP53

International Agency for Research on Cancer, Lyon, France (L.P.J., T.N.-D., S.V.T.); Université de Lyon, Institut National de la Santé et de la Recherche Médicale U590, Lyon, France (L.P.J., C.D.); and Department of Hematology, Hôpital Edouard Herriot, Lyon, France (X.T.)

mRNA expression levels of certain genes have shown predictive value for the outcome of cytarabine-treated AML-patients. We hypothesized that genetic variants play a role in the regulation of the transcription of these genes. We studied leukoblasts from 82 patients with acute myeloid leukemia and observed various extent and frequency of differential allelic expression in the CDA, DCK, NT5C2, NT5C3, and TP53 genes. Our attempts to identify the causative regulatory single nucleotide polymorphisms by a bioinformatics approach did not succeed. However, our results indicate that genetic variations are at least in part responsible for the differences in overall expression levels of these genes.